Comparative Pharmacology
Head-to-head clinical analysis: FLUNISOLIDE versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUNISOLIDE versus HYDROCORTISONE IN ABSORBASE.
FLUNISOLIDE vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation.
Clinical Note
moderateFlunisolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin."
Clinical Note
moderateFlunisolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin."
Clinical Note
moderateFlunisolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin."
Clinical Note
moderateFlunisolide + Trovafloxacin
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine.
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin."